Loading...
Chemotherapy plus Ofatumumab at standard or mega dose in relapsed CLL (COSMIC) trial: study protocol for a phase II randomised controlled trial.
Howard, D Munir, T Hockaday, A Rawstron, A Collett, L Oughton, J Allsup, D Bloor, Adrian Phillips, David Hillmen, P
Howard, D
Munir, T
Hockaday, A
Rawstron, A
Collett, L
Oughton, J
Allsup, D
Bloor, Adrian
Phillips, David
Hillmen, P
Citations
Altmetric:
Abstract
Chronic lymphocytic leukaemia (CLL) is the most common adult leukaemia. Combination immunochemotherapy such as fludarabine, cyclophosphamide and rituximab is the standard first line therapy in fit patients, but there is limited evidence regarding the optimal treatment of patients after relapse. Ofatumumab as monotherapy has been proven to be effective in the treatment of relapsed, refractory CLL, and as it is not myelotoxic, it is an ideal drug to combine with chemotherapy. However, the optimal dose of ofatumumab in this setting is not known. The Chemotherapy plus Ofatumumab at Standard or Mega dose in relapsed CLL (COSMIC) trial will assess the efficacy and safety of standard and high (mega) doses of ofatumumab combined with bendamustine or a combination of fludarabine and cyclophosphamide to determine which, if either, schedule should progress to a phase III trial.
Description
Date
2016-09-20
Publisher
Collections
Files
Keywords
Type
Article
Citation
Chemotherapy plus Ofatumumab at standard or mega dose in relapsed CLL (COSMIC) trial: study protocol for a phase II randomised controlled trial. 2016, 17 (1):456 Trials